Tenax Therapeutics Plunges 85% as Phase 3 Trial Misses Key Goals
Markets Daniel Marsh

Tenax Therapeutics Plunges 85% as Phase 3 Trial Misses Key Goals

Tenax Therapeutics (TENX) shares plummeted 85% premarket after its Phase 3 LEVEL trial failed to meet primary endpoints, erasing $425 million in market cap.

TENX
IonQ Beats Q2 Estimates but H2 Revenue Growth Looks Flat
Earnings James Calloway

IonQ Beats Q2 Estimates but H2 Revenue Growth Looks Flat

IonQ (NYSE:IONQ) reported Q2 revenue of $80.1M, beating estimates, and raised its 2026 guidance. However, implied H2 revenue suggests only marginal growth, with shares up 11.9%.

IONQ QBTS RGTI JPM
Rocket Lab and AST SpaceMobile Rise Premarket Ahead of Q2 Earnings
Earnings James Calloway

Rocket Lab and AST SpaceMobile Rise Premarket Ahead of Q2 Earnings

Rocket Lab and AST SpaceMobile shares rose in premarket trading ahead of their Q2 earnings reports. ASTS faces a challenging revenue target for the second half.

RKLB ASTS
Ferguson Beats Q2 Estimates, Raises FY2026 Outlook Amid S&P 500 Inclusion
Earnings James Calloway

Ferguson Beats Q2 Estimates, Raises FY2026 Outlook Amid S&P 500 Inclusion

Ferguson (FERG) reported Q2 adjusted EPS of $3.39, beating estimates, and raised its FY2026 sales outlook. Shares rose 1% premarket as valuation concerns persist.

FERG
Oklo's Rally Pushes Valuation to $9B Despite Early-Stage Revenue
Analysis Daniel Marsh

Oklo's Rally Pushes Valuation to $9B Despite Early-Stage Revenue

Oklo's 14.8% Friday surge lifts its market cap to $9B, but Q2 revenue of $1.2M and a $73.2M operating loss highlight the gap between valuation and execution.

OKLO SMR LEU
Barrick Shares Tumble 5% on Cost Pressures Despite $1.95B Nevada Settlement
Earnings James Calloway

Barrick Shares Tumble 5% on Cost Pressures Despite $1.95B Nevada Settlement

Barrick Mining (NYSE:B) slid 5% premarket after Q2 adjusted EPS missed estimates, overshadowing a $1.95B Nevada settlement with Newmont.

B NEM GLD
Jin Medical Shares Double Premarket After Share Count Surge
Markets Daniel Marsh

Jin Medical Shares Double Premarket After Share Count Surge

Jin Medical (NASDAQ:ZJYL) shares nearly doubled premarket as a post-deal share restructuring expanded the share count tenfold, resetting the company's valuation.

ZJYL
Doximity Soars 33% on AI Hopes, Analysts Split
Analysis Daniel Marsh

Doximity Soars 33% on AI Hopes, Analysts Split

Doximity (DOCS) surged 33% on AI revenue optimism, adding $1.2B in market value, but Wells Fargo downgraded the stock, citing unproven monetization.

DOCS WFC PIPR
B2Gold's Mali Permit Sparks Rally; Q2 Cash Flow Concerns Overlooked
Markets Daniel Marsh

B2Gold's Mali Permit Sparks Rally; Q2 Cash Flow Concerns Overlooked

B2Gold's stock rallied sharply after Mali granted a key mining permit, shifting focus from Q2 cash flow to future production growth.

BTG GDX KGC EGO
Steakholder Foods Soars on Warrant Trigger, Dilution Risk Looms
Markets Daniel Marsh

Steakholder Foods Soars on Warrant Trigger, Dilution Risk Looms

Steakholder Foods shares skyrocketed 161.6% premarket after warrants became deeply in-the-money, but the rally highlights dilution risks and funding needs.

TSMC July Sales Jump 45% as AI Demand Fuels Q3 Growth Expectations
Earnings James Calloway

TSMC July Sales Jump 45% as AI Demand Fuels Q3 Growth Expectations

TSMC's July revenue surged 44.7% year-over-year to NT$467.58 billion, propelled by AI demand. The company must maintain momentum in August and September to meet Q3 guidance.

TSM NVDA AAPL
Plug Power Stock Rises Ahead of Q2 Earnings; Cash Burn in Spotlight
Earnings James Calloway

Plug Power Stock Rises Ahead of Q2 Earnings; Cash Burn in Spotlight

Plug Power (PLUG) traded up 5.3% premarket ahead of Q2 earnings. Investors are focused on cash burn and liquidity, with revenue projected between $169.1M and $172.8M.

PLUG BLDP FCEL